Nasdaq
$0.6779▲ 4.71%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $84.4MShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.3After-hours26.09.04 05:038-KKey event#●●●#●●●
Milestone Pharmaceuticals Inc.Bullish
Milestone Pharmaceuticals has received approval from China's NMPA for its etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT). This regulatory milestone triggers a $2.0 million payment to the company, with potential for up to $98.0 million in additional milestone payments and tiered royalties of up to 18% on future sales in Greater China.…more
$0.6779+4.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12Pre-market26.08.12 20:288-KKey event
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals reported $0.56 million in revenue and a net loss of $28.61 million ($0.21 per share) for the second quarter of 2026. Insurance coverage for its lead product, CARDAMYST, has expanded to approximately 50% in the U.S., and the Phase 3 trial for the AFib-RVR indication has been initiated. As of June 30, 2026, the company holds $170.6 million in cash and equivalents, providing a financial runway through the second half of 2027.…more
$0.6779+4.71%vs prev closeView filingShare - 8.12Pre-market26.08.12 20:0110-QEarnings
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals extended the deferral period for interest payments on its $50 million convertible senior secured notes from March 31, 2026, to March 31, 2027, through a third amendment to the note purchase agreement dated June 29, 2026. Additionally, under a second amendment dated January 12, 2026, the company secured approval for royalty financing and the release of liens on its revenue participation rights.…more
$0.6779+4.71%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●
Milestone Pharmaceuticals to Present Clinical Data at Upcoming Cardiology Conferences…more
Milestone Pharmaceuticals announced it will present clinical data and program updates for its cardiovascular drug, CARDAMYST, at three upcoming cardiology conferences. These presentations focus on sharing existing clinical trial results and ongoing research rather than new commercial agreements or financial milestones.…more
$0.6779+4.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.9Pre-market26.10.09 21:00
●●●●●●●● ●●●●● ●●●●●●
Milestone Pharmaceuticals has enrolled its first European patient in the Phase 3 clinical trial for Etripamil, a treatment for atrial fibrillation. While this marks progress in clinical development, it remains a neutral event as the drug is still in the testing phase.…more
$0.6779+4.71%vs prev closeShareBenzinga - 9.24Pre-market26.09.24 21:00
●●●●●●●● ●●●●● ●●●●●●
Milestone Pharmaceuticals has expanded its Phase 3 pivotal trial for the nasal spray etripamil to Canada, enrolling its first patient at the Montreal Heart Institute. The study aims to evaluate the efficacy of the self-administered treatment for patients with atrial fibrillation with rapid ventricular rate.…more
$0.6779+4.71%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report